Iran reveals plans to domestically produce 135 strategic drugs

pharmafile | September 26, 2019 | News story | Manufacturing and Production Iran, pharma, production 

Iran has announced plans to promote self-sufficiency within the country with regard to its medicines production, with an aim of producing 135 strategic pharmaceutical products within its borders.

According to the Information Center of Iran’s National Elites Foundation, the nation’s Vice President for Science and Technology Affairs, Sorena Sattari, was quoted as saying:  “We have initiated the programme of self-efficacy in drug production since last year. In this regard, 27 biological drugs, 50 chemical drugs, and 58 raw materials that generate the foreign currency drain will be created in Iran with the help of knowledge-based companies and start-ups.”

This could provide an alternative, cheaper means of production to the “foreign currency drain” of $570 million that the country spends currently on these products.

Sattari added: “One of the steps taken by the Vice Presidency in support of domestic producers is realisation of customs exemptions. We have aimed to introduce effective exemptions to contribute to the development of companies and production of new and innovative products.”

Sattari was present at the fifth Iran Pharma Expo alongside the country’s Minister of Health, Head of Food and Drug Organization, and Economic Deputy Minister of Foreign Affairs at the Imam Khomeini Musalla in Tehran. The event was attended by over 400 domestic and 150 foreign companies.

Matt Fellows

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

kidney

Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content